Diclofenac Shortage: What Providers and Prescribers Need to Know in 2026

Diclofenac is among the most commonly prescribed NSAIDs in the United States, accounting for over 9 million prescriptions in 2023 and treating a wide spectrum of inflammatory and pain conditions. This briefing provides clinicians with a current overview of Diclofenac availability, formulation-specific access issues, evidence-based therapeutic alternatives, and practical tools to reduce prescription abandonment among your patient population.

Current Shortage Status (2026)

There is no active nationwide shortage of Diclofenac listed with the FDA or ASHP as of 2026. Generic diclofenac sodium tablets (25 mg, 50 mg, 75 mg, 100 mg delayed-release and extended-release) are produced by multiple manufacturers and are broadly available in community pharmacy settings. OTC Voltaren Gel 1% has been widely available since its FDA OTC approval in 2020.

However, clinicians should be aware that certain formulations have more variable community pharmacy availability:

Cambia (diclofenac potassium 50 mg oral powder): Limited stocking; may require pharmacy ordering. Consider prescribing with a note that a generic equivalent is acceptable if insurance allows.

Zorvolex (18 mg / 35 mg diclofenac capsules): Lower market penetration; not stocked at all community pharmacies.

Zipsor (25 mg diclofenac potassium capsules): Similar stocking limitations as Zorvolex.

Pennsaid 1.5% / 2% topical solution: Prescription-required; limited formulary coverage on many plans, may require prior authorization.

Dyloject (diclofenac sodium IV 37.5 mg/mL): Hospital formulary dependent; availability varies by institution.

Formulary and Insurance Considerations

Generic diclofenac sodium is on virtually all commercial and Medicare Part D formularies as a Tier 1 or Tier 2 medication. Patient out-of-pocket costs for generics typically range from $0–$30 for a 30-day supply. However, clinicians should be aware of several formulary dynamics that affect patient access:

Preferred generic programs: Some plans designate specific generic manufacturers as preferred. If your patient's plan switched preferred generic suppliers, they may see a temporary gap in availability.

Prior authorization for topical formulations: Pennsaid and prescription topical diclofenac often require PA documentation that OTC or oral alternatives were tried and insufficient.

Quantity limits: Some plans impose quantity limits on diclofenac patches (Flector/Licart). Confirm quantities before submitting to reduce claim rejections.

Evidence-Based Therapeutic Alternatives

When Diclofenac is unavailable or contraindicated, the following alternatives are supported by clinical evidence for common indications:

For Osteoarthritis / Rheumatoid Arthritis:

Meloxicam 7.5–15 mg once daily: Most analogous to diclofenac pharmacologically (preferential COX-2); once-daily dosing improves adherence; broadly generic; low cost.

Celecoxib 100–200 mg BID: Preferred for patients with high GI risk (prior PUD, anticoagulant use, advanced age). Selective COX-2 inhibition reduces GI bleeding risk. Generic available.

Naproxen 250–500 mg BID or naproxen sodium 275–550 mg BID: Effective; long half-life; broad generic availability; evidence-based for OA and RA per ACR guidelines.

For Migraine (Cambia-equivalent need):

Naproxen sodium 550 mg at onset, may repeat once; or ibuprofen 400 mg at onset are guideline-supported first-line options for mild-to-moderate migraine when triptans are not preferred.

Sumatriptan or other triptans remain preferred for moderate-to-severe migraine.

For Localized Joint Pain (Topical Need):

OTC Voltaren Gel 1% is an appropriate substitution when prescription topical diclofenac is unavailable. It delivers the same active ingredient and the ACR guidelines for knee and hand OA support topical NSAIDs as first-line therapy.

Cardiovascular and Safety Profile Considerations When Switching

Diclofenac has a relatively higher cardiovascular risk profile among NSAIDs due to its preferential COX-2 inhibition — comparable to celecoxib and somewhat higher than naproxen in head-to-head cardiovascular outcome studies (PRECISION trial). When switching patients:

Naproxen has the most favorable cardiovascular risk profile among oral NSAIDs and is preferred in patients with established cardiovascular disease.

Diclofenac's hepatotoxicity risk is somewhat higher than other NSAIDs. Monitor transaminases periodically for patients on long-term therapy.

All NSAIDs carry boxed warnings for cardiovascular thrombotic events and GI bleeding. Use the lowest effective dose for the shortest duration necessary.

Reducing Prescription Abandonment: A Practical Tool for Your Patients

Prescription abandonment increases when patients can't fill their medication at the first pharmacy they try. medfinder for providers is a service that calls pharmacies near a patient's location to identify which ones can fill their prescription. This is particularly useful for specialty formulations of Diclofenac that aren't routinely stocked.

For a patient-facing version of this shortage update, see our Diclofenac shortage patient guide.